Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trialReport as inadecuate




Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial - Download this document for free, or read online. Document in PDF available to download.

Cardiovascular Diabetology

, 10:58

First Online: 30 June 2011Received: 01 March 2011Accepted: 30 June 2011

Abstract

BackgroundAlthough the ADA-EASD-IDF International Expert Committee recommends using hemoglobin A1c HbA1c to define diabetes, the relation between HbA1c and cardiovascular disease CVD has not been thoroughly investigated. We analyzed this relation using clinical data on Japanese individuals with hypercholesterolemia.

MethodsIn the large-scale MEGA Study 7832 patients aged 40 to 70 years old with mild-to-moderate hypercholesterolemia without CVD were randomized to diet alone or diet plus pravastatin and followed for >5 years. In the present subanalysis of that study a total of 4002 patients with baseline and follow-up HbA1c data were stratified according to having an average HbA1c during the first year of follow-up <6.0%, 6.0%-<6.5%, or ≥6.5% and their subsequent 5-year incidence rates of CVD compared according to sex, low-density lipoprotein cholesterol LDL-C, and treatment arm.

ResultsOverall, risk of CVD was significantly 2.4 times higher in individuals with HbA1c ≥6.5% versus <6.0%. A similar relation was noted in men and women hazard ratio HR, 2.1; p <0.01 and HR, 3.0; p <0.01, respectively and was regardless of treatment arm diet alone group: HR, 2.2; p <0.001; diet plus pravastatin group: HR, 1.8; p = 0.02. Spline curves showed a continuous risk increase according to HbA1c level in all subpopulations studied.

ConclusionsIn hypercholesterolemic individuals the risk of CVD increases linearly with HbA1c level. This significant contribution by elevated HbA1c to increased CVD is independent of pravastatin therapy, and thus requires appropriate HbA1c management in addition to lipids reduction.

KeywordsHemoglobin A1c HbA1c cardiovascular disease CVD hypercholesterolemia HMG CoA reductase inhibitor pravastatin, MEGA Study Electronic supplementary materialThe online version of this article doi:10.1186-1475-2840-10-58 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Rimei Nishimura - Tomoko Nakagami - Hirohito Sone - Yasuo Ohashi - Naoko Tajima

Source: https://link.springer.com/article/10.1186/1475-2840-10-58







Related documents